{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:23:36Z","timestamp":1792113816120,"version":"4.4.0"},"reference-count":59,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment. However, echinocandins are only available intravenously and are associated with increasingly higher rates of resistance by C. auris. Thus, a need exists for novel treatments that demonstrate potent activity against C. auris. Ibrexafungerp is a first-in-class triterpenoid antifungal agent. Similar to echinocandins, ibrexafungerp inhibits (1\u21923)-\u03b2-D-glucan synthase, a key component of the fungal cell wall, resulting in fungicidal activity against Candida spp. Ibrexafungerp demonstrates broad in vitro activity against various Candida spp. including C. auris and C. auris isolates with fks mutations. Minimum inhibitory concentration (MIC50 and MIC90) values in &gt;400 C. auris isolates were 0.5 \u03bcg\/mL and 1.0 \u03bcg\/mL, respectively. Clinical results were reported for two patients with invasive candidiasis or candidemia due to C. auris treated during the CARES (Candidiasis Caused by Candida Auris) trial, an ongoing open-label study. These patients experienced a complete response after treatment with ibrexafungerp. Thus, ibrexafungerp represents a promising new antifungal agent for treating C. auris infections.<\/jats:p>","DOI":"10.3390\/antibiotics9090539","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T09:24:56Z","timestamp":1598347496000},"page":"539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections"],"prefix":"10.3390","volume":"9","author":[{"given":"Mahmoud","family":"Ghannoum","sequence":"first","affiliation":[{"name":"Department of Dermatology, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4747-0144","authenticated-orcid":false,"given":"Maiken Cavling","family":"Arendrup","sequence":"additional","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, DK-2300 Copenhagen, Denmark"},{"name":"Department of Clinical Microbiology, Rigshospitalet, DK-2100 Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, DK-2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu P.","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"New York State Department of Health Wadsworth Center, Albany, NY 12201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn R.","family":"Lockhart","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"McCormick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Case Western Reserve University, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"New York State Department of Health Wadsworth Center, Albany, NY 12201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Berkow","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA 30333, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deven","family":"Juneja","sequence":"additional","affiliation":[{"name":"Max Super Specialty Hospital, 110017 New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bansidhar","family":"Tarai","sequence":"additional","affiliation":[{"name":"Max Super Specialty Hospital, 110017 New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkechi","family":"Azie","sequence":"additional","affiliation":[{"name":"Scynexis Inc., 1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Angulo","sequence":"additional","affiliation":[{"name":"Scynexis Inc., 1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine of Cornell University, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wickes, B.L. (2020). Analysis of a Candida auris Outbreak Provides New Insights into an Emerging Pathogen. J. Clin. Microbiol., 58.","DOI":"10.1128\/JCM.02083-19"},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (2020, June 30). Tracking Candida Auris, Available online: https:\/\/www.cdc.gov\/fungal\/candida-auris\/tracking-c-auris.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cid\/ciw696","article-title":"Emergence of Candida auris: An International Call to Arms","volume":"64","author":"Clancy","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chowdhary, A., Sharma, C., and Meis, J.F. (2017). Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLOS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006290"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhu, Y., O\u2019Brien, B., Leach, L., Clarke, A., Bates, M., Adams, E., Ostrowsky, B., Quinn, M., Dufort, E., and Southwick, K. (2019). Laboratory Analysis of an Outbreak of Candida auris in New York from 2016 to 2018: Impact and Lessons Learned. J. Clin. Microbiol., 58.","DOI":"10.1101\/760090"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sabino, R.F.P., Ver\u00edssimo, C., Pereira, \u00c1.A., and Antunes, F. (2020). Candida auris, An Agent of Hospital-Associated Outbreaks: Which Challenging Issues Do We Need to Have in Mind?. Microorganisms, 8.","DOI":"10.3390\/microorganisms8020181"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/IDR.S249864","article-title":"Candida auris: From Multidrug Resistance to Pan-Resistant Strains","volume":"13","author":"Ademe","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103243","DOI":"10.1016\/j.fgb.2019.103243","article-title":"Candida auris and multidrug resistance: Defining the new normal","volume":"131","author":"Lockhart","year":"2019","journal-title":"Fungal Genet. Boil."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3389\/fmicb.2019.02788","article-title":"Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris","volume":"10","author":"Chaabane","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mmy\/myy054","article-title":"Candida auris: The recent emergence of a multidrug-resistant fungal pathogen","volume":"57","author":"Forsberg","year":"2018","journal-title":"Med. Mycol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13054-019-2449-y","article-title":"The global challenge of Candida auris in the intensive care unit","volume":"23","author":"Cortegiani","year":"2019","journal-title":"Crit. Care"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Caceres, D.H., Forsberg, K., Welsh, R.M., Sexton, D.J., Lockhart, S.R., Jackson, B.R., and Chiller, T. (2019). Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings. J. Fungi, 5.","DOI":"10.3390\/jof5040111"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3201\/eid2410.180649","article-title":"Candida auris in Healthcare Facilities, New York, NY, USA, 2013\u20132017","volume":"24","author":"Adams","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e02195-19","DOI":"10.1128\/AAC.02195-19","article-title":"In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak","volume":"64","author":"Chaturvedi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"105922","DOI":"10.1016\/j.ijantimicag.2020.105922","article-title":"Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor)","volume":"55","author":"Zhu","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3201\/eid2605.191588","article-title":"Clinical Outcomes of Patients Treated for Candida auris Infections in a Multisite Health System, IL, USA","volume":"26","author":"Arensman","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15585\/mmwr.mm6901a2","article-title":"Candida auris Isolates Resistant to Three Classes of Antifungal Medications\u2014New York","volume":"69","author":"Ostrowsky","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1016\/j.bmcl.2012.05.031","article-title":"Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of \u03b2-1,3-glucan synthase","volume":"22","author":"Heasley","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/mmy\/myz083","article-title":"Ibrexafungerp: A novel oral glucan synthase inhibitor","volume":"58","author":"Davis","year":"2020","journal-title":"Med. Mycol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e00833-17","DOI":"10.1128\/AAC.00833-17","article-title":"De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance","volume":"61","author":"Perez","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e00161-17","DOI":"10.1128\/AAC.00161-17","article-title":"Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00435-17","DOI":"10.1128\/AAC.00435-17","article-title":"In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris","volume":"61","author":"Berkow","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"AAC.01510-19","DOI":"10.1128\/AAC.01510-19","article-title":"Activity of a Novel 1,3-Beta-D-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata","volume":"63","author":"Ghannoum","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00244-18","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e02396-16","DOI":"10.1128\/AAC.02396-16","article-title":"The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation","volume":"61","author":"Larkin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/jac\/dkx010","article-title":"The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.","volume":"72","author":"Escribano","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E01692-19","DOI":"10.1128\/AAC.01692-19","article-title":"In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations","volume":"63","author":"Nunnally","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","unstructured":"Rautermaa-Richardson, R., Moore, C.B., and Rawson, K. (2019, January 11\u201314). Aspergillus isolates from patients with chronic pulmonary aspergillosis mycologically and clinically resistant to azole antifungals are sensitive to ibrexafungerp (SCY-078). Presented at the 9th Congress on Trends in Medical Mycology, Nice, France."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e01961-16","DOI":"10.1128\/AAC.01961-16","article-title":"SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies","volume":"61","author":"Scorneaux","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhu, Y.C., Barat, S.A., Borroto-Esoda, K., Angulo, D., Chaturvedi, S., and Chaturvedi, V. (2019). In vitro Efficacy of Novel Glucan Synthase Inhibitor, Ibrexafungerp (SCY-078), Against Multidrug- and Pan-resistant Candida auris Isolates from the Outbreak in New York. BioRxiv.","DOI":"10.1101\/811182"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e02136-19","DOI":"10.1128\/AAC.02136-19","article-title":"In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Barat, S., and Borroto-Esoda, A.D. (2018, January 25\u201328). Ibrexafungerp (SCY-078): A first-in-class, orally-bioavailable, glucan synthase inhibitor has fungicidal activity against C. auris, an emerging multidrug-resistant pathogen. Presented at the 2018 Mycoses Study Group Education and Research Consortium, Big Sky, MT, USA.","DOI":"10.26226\/morressier.5ac39997d462b8028d89a2db"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jac\/dkx422","article-title":"Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ghannoum, M., Isham, N., Angulo, D., Borroto-Esoda, K., Barat, S., and Long, L. (2020). Efficacy of Ibrexafungerp (SCY-078) Against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model. Antimicrob. Agents Chemother., AAC.00854-20.","DOI":"10.1128\/AAC.00854-20"},{"key":"ref_37","unstructured":"Ghannoum, M., Long, L., Hager, C., Borroto-Esoda, K., Barat, S., and Angulo, D. (2019). Efficacy of oral ibrexafungerp (IBX, Formerly SCY-078) in the treatment of Candida auris infection in a murine disseminated model. ASM Microbe."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using anIn VivoMurine Invasive Candidiasis Model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e02611-18","DOI":"10.1128\/AAC.02611-18","article-title":"A Novel 1,3-Beta-D-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis","volume":"63","author":"Larkin","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e02068-16","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e02119-18","DOI":"10.1128\/AAC.02119-18","article-title":"SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [14C]SCY-078 in Albino and Pigmented Rats","volume":"63","author":"Wring","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpdd.588","article-title":"Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus","volume":"8","author":"Wring","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_43","unstructured":"Trucksis, M., Garrett, G., and Heirman, I. (2010, January 12\u201315). A phase I single rising dose study evaluating the safety, tolerability and pharmacokinetics of an oral glucan synthase inhibitor in healthy male volunteers. Proceedings of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, USA."},{"key":"ref_44","unstructured":"Murphy, G., Darpo, B., and Marbury, T. (2017). Lack of an effect of SCY-078 a novel antifungal agent on QTc interval in healthy subjects. Abstracts of ASM Microbe, ASM Press. Abstract 172."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/jcph.1146","article-title":"Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions","volume":"58","author":"Wring","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_46","unstructured":"Murphy, G., Hyman, M., and Willett, M. (2017). CYP-mediated drug interaction profile of SCY-078, a novel glucan synthase inhibitor (GSI). Abstracts of ASM Microbe, ASM Press. Abstract 173."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Barat, S., and Borroto-Esoda, A.D. (2020, January 18\u201321). Ibrexafungerp demonstrates potent and consistent in vitro activity against >400 global Candida auris isolates, including isolates with elevated MIC\u2019s to echinocandins. Proceedings of the ECCMID, Paris, France.","DOI":"10.1093\/ofid\/ofaa439.925"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/mmy\/myz112","article-title":"Comparison of risk factors and outcomes of Candida auris candidemia with non-Candida auris candidemia: A retrospective study from Pakistan","volume":"58","author":"Sayeed","year":"2019","journal-title":"Med Mycol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcrc.2020.01.004","article-title":"Candida auris candidaemia in an intensive care ujit-prospective observational study to evaluate epidemiology, risk factors, and outcome","volume":"57","author":"Akrabarti","year":"2020","journal-title":"J. Crit. Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/nprot.2008.192","article-title":"In vitro growth and analysis of Candida biofilms","volume":"3","author":"Chandra","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_51","unstructured":"Hager, C.L., Sun, P.-L., and Fujioka, H. (2018, January 8\u201310). Morphological effect of SCY-078 and caspofungin on different caspofungin-resistant Candida species. Presented at ASM Microbe, Atlanta, GA, USA."},{"key":"ref_52","unstructured":"Juneja, D., Singh, O., Tarai, B., and Angulo, D. (2019). Sucessful Treatment of Two patienTs with Candida Auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study, European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Poster no. L0028."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dkx480","article-title":"A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance","volume":"73","author":"Chowdhary","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/myc.13022","article-title":"Candida auris in various hospitals across Kuwait and their susceptibility and molecular basis of resistance to antifungal drugs","volume":"63","author":"Ahmad","year":"2020","journal-title":"Mycoses"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e00238-18","DOI":"10.1128\/AAC.00238-18","article-title":"Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris","volume":"62","author":"Kordalewska","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Biagi, M.J., Wiederhold, N.P., Gibas, C., Wickes, B.L., Lozano, V., Bleasdale, S.C., and Danziger, L. (2019). Development of High-Level Echinocandin Resistance in a Patient with Recurrent Candida auris Candidemia Secondary to Chronic Candiduria. Open Forum Infect. Dis., 6.","DOI":"10.1093\/ofid\/ofz262"},{"key":"ref_57","first-page":"43","article-title":"Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris","volume":"7","author":"Rhodes","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Petraitis, V., Petraitiene, R., Katragkou, A., Maung, B.B.W., Naing, E., Kavaliauskas, P., Barat, S., Borroto-Esoda, K., Azie, N., and Angulo, D. (2020). Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1\u21923)-\u03b2-D-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02429-19"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1093\/jac\/dkz277","article-title":"MSG-10: A Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis","volume":"74","author":"Spec","year":"2019","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/9\/539\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:06:11Z","timestamp":1760177171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/9\/539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":59,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["antibiotics9090539"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9090539","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,25]]}}}